
## Midazolam Newborn use only

Alert	S4Drug – High risk medica	tion causing significant pa	atient harm when used in error.
Indication	Sedation during ventilation or procedure.		
	Treatment of refractory se		
Action			nediated by gamma-aminobutyric acid (GABA) by
	accumulation and occupat	tion of benzodiazepine re	ceptors. Anti-anxiety properties are related to
	increasing the glycine inhi	bitory neurotransmitter.	
Drug type	Short acting benzodiazepi	ne.	
Trade name	Hypnovel, Midazolam Alphapharm, Midazolam Pfizer, Midazolam-Baxter, B. Braun Midazolam,		
	Midazolam Accord, Midaz		
Presentation	5mg/mL, 5mg/5mL, 50mg	/10mL, and 15mg/3mL a	mpoules for IV and oral use.
Dose		4.5	
	Method	Dose <sup>1-5</sup>	
	IV infusion for sedation	0.2–1 microgram/kg/m	inute
	IV infusion for seizures	Loading doco: 150-200	microgram/kg over 3–5 minutes
	IV III usion for seizures	Maintenance dose: 1–7	
	IV bolus		every 2 hours when required.
		(Dose range: 50–150 m	
	IM injection		every 4 hours when required.
		(Dose range: 50–150 m	
	Oral	250 microgram/kg as a	
	Sublingual/buccal	200 microgram/kg as a	
	Intranasal	200 microgram/kg per o	dose as a single dose
		(Dose range: 200–300 r	nicrogram/kg/dose)
Dose adjustment	Therapeutic hypothermia	-	-
	ECMO – Increased volume of distribution but reduced renal clearance and accumulation of active		
		gher dose may be require	d in early stages of ECMO. Close monitoring is
	recommended. <sup>7</sup>		
	Renal impairment – Limite		
Maximum dose	Hepatic Impairment – For	repeated doses and IV in	fusion, reduction in dosage may be required.
Total cumulative dose			
Route	IV, IM, Oral, Sublingual.		
Noute	IV, IM, Oral, Sublingual. Intranasal (not recommended due to nasal irritation; only under exceptional circumstances, e.g. acute		
	refractory seizures with no		
Preparation	IV infusion for:		- 1
·	Sedation using 5 mg/1 mL	<u>strength</u>	
	Infusion	<u>strength</u>	Prescribed amount
	<u>1 mL/hour = 1 microgran</u>		3 mg/kg midazolam and make up to 50 mL
	Draw up 0.6 mL/kg (3 mg/kg of midazolam) and add glucose 5%, glucose 10%, or sodium chloride 0.9%		
	to make final volume 50 mL. Infusing at a rate of 1 mL/ hour = 1 microgram/kg/minute.		
	IV bolus using this solution: 0.83 mL= 50 micrograms/kg		
	Sodation using Emg/E ml strongth		
	Sedation using 5mg/5 mL strength		
	Infusion	strongth	Dressrihad amount
			Prescribed amount 3 mg/kg midazolam and make up to 50 mL
	1 mL/hour = 1 microgram/kg/minute       3 mg/kg midazolam and make up to 50 mL         Draw up 3 mL/kg (3 mg/kg of midazolam) and add glucose 5%, glucose 10%, or sodium chloride 0.9% to		
	make final volume 50 mL. Infusing at a rate of 1 mL/ hour = 1 microgram/kg/minute.		
	<b>IV bolus</b> using this solution: 0.83 mL = 50 micrograms/kg		
	Seizures using 5 mg/1 mL		

	Infusion strength	Prescribed amount		
	<u>1 mL/hour = 5 microgram/kg/minute</u>	<u>15 mg/kg midazolam and make up to 50mL</u>		
	Draw up 3 mL/kg (15 mg/kg of midazolam) an make final volume 50 mL. <b>Infusing at a rate o</b>	d add glucose 5%, glucose 10%, or sodium chloride 0.9% to f 1 mL/hour = 5 microgram/kg/minute.		
	Seizures using 5 mg/5 mL strength – Can be used for babies up to 3300 g.			
	Infusion strength	Prescribed amount		
	<u>1 mL/hour = 5 microgram/kg/minute</u>	15 mg/kg midazolam and make up to 50mL		
	Draw up 15 mL/kg (15 mg/kg of midazolam) a to make final volume 50 mL. <b>Infusing at a rate</b>	nd add glucose 5%, glucose 10%, or sodium chloride 0.9% e of 1 mL/hour = 5 microgram/kg/minute.		
	<ul> <li>IV bolus, IM, oral, sublingual</li> <li><u>Using 5 mg/mL ampoule</u></li> <li>Draw up 0.4 mL (2000 microgram of midazolam) and add 9.6 mL of sodium chlorid</li> <li>make final volume of 10 mL with a concentration of 200 microgram/mL.</li> <li><u>Using 5 mg/5mL ampoule</u></li> <li>Draw up 1 mL (1000 microgram of midazolam) and add 4 mL of sodium chloride 0 final volume of 5 mL with a concentration of 200 microgram/mL.</li> </ul>			
	Infant < 3kg Draw up 0.2 mL (1000 microgram of midazolam) and add 0.8 mL of sodium chlori make a final volume of 1 ml and concentration of 1 mg/mL (1000 microgram/mL) Recommended maximum volume in each nostril: 0.3 mL. Larger volumes may en nasopharynx. <sup>24</sup> Infant ≥ 3kg			
	Draw up 0.4 mL (2000 microgram of make a final volume of 1 ml and conc	midazolam) and add 0.6 mL of sodium chloride 0.9% to centration of 2 mg/mL (=2000 microgram/mL). each nostril: 0.3 mL. Larger volumes may end up in the		
Administration	IV infusion: continuous infusion via a syringe IV bolus: slow push over 10 minutes. <sup>8</sup>	oump. Change solution every 24 hours.		
	•	n <b>plastic</b> IV ampoules may be used for oral or sublingual		
	maximum effect in 10 minutes and durati Mucosal atomisation device (MAD):	ernating nostrils over 15 seconds. Absorption is rapid; on up to 2 hours. May be irritating to nasal mucosa.		
	<ul><li>solution to the prescribed dose.</li><li>Insert the MAD loosely into the nostr</li><li>Briskly compress the syringe plunger</li></ul>	r- lock syringe and prime the device with the midazolam il to form a seal, preventing expulsion of fluid. to allow for maximal coverage of nasal mucosa with		
Monitoring	atomised particles. Apnoea, respiratory depression. Blood pressure. Level of sedation.			
Contraindications	Known hypersensitivity to midazolam.			
Precautions		erm, midazolam half-life is increased from 4–6 hours in		

	Caution when concurrently used with opioids – midazolam interacts with other central nervous system (CNS) depressants and may increase the risk of drowsiness, respiratory depression, and hypotension.
	Withdraw slowly after chronic administration as abrupt discontinuation may precipitate withdrawal seizures.
	Caution in neonates with renal and hepatic impairment – increased sensitivity to CNS effects; use doses
	at lower end of the range.
	Rapid IV infusion may result in hypotension, respiratory depression, or seizure.
Drug interactions	Concurrent administration with erythromycin promotes accumulation.
Drug interactions	Xanthines may decrease the anaesthetic/sedative effect of benzodiazepines. Care needs to be taken with
	adding or withdrawing caffeine or aminophylline.
Adverse	Hypotension and reduced cardiac output, particularly when used in combination with fentanyl.
reactions	Respiratory depression and apnoea.
reactions	Hypersalivation.
	Nasal discomfort (with intranasal route).
	Seizure-like myoclonus (more common in premature neonates receiving via intravenous route). <sup>9</sup>
Overdose	Flumazenil is a specific benzodiazepine receptor antagonist.
	Dose: 10 microgram/kg IV bolus followed by repeat boluses (1-2 min) or 5 microgram/kg/min IV infusion
	until sedation reversed or maximum dose of 50 microgram/kg is reached. <sup>10</sup>
Compatibility	Fluids: Glucose 5%, glucose 10%, sodium chloride 0.9%, and sodium chloride 0.45%.
companionity	
	Y-site <sup>11</sup> : Amino acid solutions. Acetaminophen, amikacin, amiodarone, atracurium, atropine, aztreonam,
	calcium chloride, calcium gluconate, caspofungin, cefazolin, cefotaxime, cefoxitin, ceftriaxone,
	ciprofloxacin, dexmedetomidine, digoxin, diltiazem, dopamine, doxycycline, enalaprilat, epinephrine,
	erythromycin lactobionate, fentanyl, fluconazole, folic acid (as sodium salt), gentamicin, glycopyrrolate,
	heparin, isoproterenol, ketamine, labetolol, lidocaine, linezolid, lorazepam, magnesium sulfate,
	metronidazole, milrinone, morphine hydrochloride, morphine sulfate, multiple vitamin injection,
	naloxone, nitroglycerin, nitroprusside sodium, norepinephrine, octreotide, oxacillin, pamidronate,
	pancuronium, papaverine, penicillin G potassium, penicillin G sodium, pentoxyfylline, piperacillin,
	potassium chloride, procainamide, propranolol, protamine sulfate, pyridoxine, ranitidine, remifentanil,
	rocuronium, streptokinase, theophylline, ticarcillin, ticarcillin-clavulanate, tobramycin, urokinase,
	vancomycin, vasopressin, vecuronium, and verapamil.
	Variable compatibility <sup>11</sup> : amoxicillin-clavulanate, clindamycin, clonidine, dobutamine, furosemide,
	hydralazine, imipenem-cilastatin, insulin, regular, methylprednisolone sodium succinate, pantoprazole,
	propofol, SMOFlipid (up to 0.5 mg/mL midazolam concentration) <sup>23</sup> , and sodium acetate.
Incompatibility	Fluids: No information.
	Y-site: Aciclovir, albumin, aminophylline, amoxicillin, amphotericin B cholesteryl sulfate complex,
	amphotericin B conventional colloidal, amphotericin B lipid complex, amphotericin B liposome,
	ampicillin, atenolol, azathioprine, azithromycin, cefepime, ceftazidime, chloramphenicol, cloxacillin,
	dexamethasone, diazepam, diazoxide, epoetin alfa, esomeprazole, flucloxacillin, fluorouracil, ganciclovir,
	hydrocortisone sodium succinate, ibuprofen lysine, indomethacin, omeprazole, phenobarbital
	(phenobarbitone), phenytoin, piperacillin-tazobactam, potassium acetate, sodium bicarbonate,
	sulfamethoxazole-trimethoprim, and thiopental. <sup>11</sup>
Stability	Diluted solution: Store at 2–8°C and use within 24 hours.
Storage	Midazolam Apotex, Midazolam-Baxter: Store below 30°C. Protect from light.
-	B. Braun Midazolam, Hypnovel, Midazolam Alphapharm: Store below 25°C. Protect from light.
	Midazolam Pfizer: Store below 25°C. Protect from light. Unopened ampoules will be suitable for use for
	up to 8 months after the foil sachet has been opened, if protected from light.
	Schedule 4D (S4D) medication. Store in dangerous drug safe and record use in S4D register.
Excipients	Sodium chloride, hydrochloric acid, sodium hydroxide, and water for injections.
Special	Flumazenil is a specific benzodiazepine antagonist and may be used (very limited experience in the
comments	neonate) to rapidly reverse respiratory depression – 10 microgram/kg/dose IV push.
	May repeat every minute for up to 4 more doses.
Evidence	Efficacy
	Sedation

2024



	3 min after child returned to recovery after surgery. Children who received flumazenil woke up 4 times faster compared to the placebo group. The average total dose of flumazenil administered was 24(±19)		
	microgram/kg. <sup>10</sup>		
	<ul> <li>Pharmacokinetics</li> <li>Midazolam is highly protein bound with an elimination half-life of 4–6 hours in term neonates and a variable half-life (up to 22 hours) in premature neonates and those with impaired hepatic function.</li> <li>Bioavailability is approximately 36% with oral administration and 50% with sublingual and intranasal administration.<sup>20</sup> (Level III, Grade C). Pharmacokinetic data favours low dose of IV infusion for sedation in very preterm neonates compared to more mature neonates.<sup>1</sup></li> </ul>		
Practice points			
References	<ol> <li>Völler S, Flint RB, Beggah F, et. Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model. J Clin Pharmacol. 2019 Oct;59(10):1300-1308.</li> </ol>		
	2. Castro Conde JR, Hernandez Borges AA, Domenech Martinez E, et al. Midazolam in neonatal seizures with no response to phenobarbital. Neurology. Mar 8, 2005;64(5):876–879.		
	3. Castro Conde JR, González Campo C, et al. High Effectiveness of Midazolam and Lidocaine in the Treatment of Acute Neonatal Seizures. J Clin Neurophysiol. 2024 Jul 1;41(5):450-457.		
	<ol> <li>Milési C, Baleine J, Mura T, et al. Nasal midazolam vs ketamine for neonatal intubation in the delivery room: a randomised trial Arch Dis Child Fetal Neonatal Ed 2018; 103: F221–F226.</li> </ol>		
	5. Fişgin T, Gürer Y, Senbil N, et al. Nasal midazolam effects on childhood acute seizures. J Child Neurol 2000 Dec; 15(12):833-5.		
	<ol> <li>Favié, Laurent M A et al. "Phenobarbital, Midazolam Pharmacokinetics, Effectiveness, and Drug-Drug Interaction in Asphyxiated Neonates Undergoing Therapeutic Hypothermia." Neonatology vol. 116, 2 (2019): 154-162.</li> </ol>		
	<ol> <li>Raffaeli G, Pokorna P, Allegaert K, et al. Drug Disposition and Pharmacotherapy in Neonatal ECMO: From Fragmented Data to Integrated Knowledge. Front Pediatr. 2019; 7:360. Published 2019 Sep 3. doi:10.3389/fped.2019.00360</li> </ol>		
	<ol> <li>Van Den Broek MP, Van Straaten HL, Huitema AD, et al. Anticonvulsant effectiveness and hemodynamic safety of midazolam in full-term infants treated with hypothermia. Neonatology. 2015 Jan 8;107(2):150-6.</li> </ol>		
	9. Gupta MK, Mondkar JA, Hegde D. Paradoxical Reaction to Midazolam in Preterm Neonates: A Case Series. Indian J Crit Care Med. 2018 Apr;22(4):300-302.		
	10. Jones RD, Lawson AD, Andrew LJ, et al. Antagonism of the hypnotic effect of midazolam in children: a randomized, double-blind study of placebo and flumazenil administered after midazolam-induced anaesthesia. Br J Anaesth. 1991 Jun;66(6):660-6.		
	11. Micromedex online. Midazolam. Accessed on 21 April 2021.		
	12. Ng E, Taddio A, Ohlsson A. Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No.: CD002052.		
	<ol> <li>Ku LC, Simmons C, Smith PB, et al. Intranasal midazolam and fentanyl for procedural sedation and analgesia in infants in the neonatal intensive care unit. J Neonatal Perinatal Med. 2019;12(2):143- 148.</li> </ol>		
	14. Lawrence C. Ku, Catherine Simmons, Brian Smith, et al. Pediatrics Jan 2018, 141 (1 Meeting Abstract 532; DOI: 10.1542/peds.141.1 MeetingAbstract.532.		
	<ol> <li>Humphries LK, Eiland LS. Treatment of acute seizures: is intranasal midazolam a viable option? J Pediatr Pharmacol Ther. 2013 Apr;18(2):79-87.</li> </ol>		
	16. de Tristan MA, Martin-Marchand L, Roué JM, et al. Association of Continuous Opioids and/or Midazolam During Early Mechanical Ventilation with Survival and Sensorimotor Outcomes at Age 2 Years in Premature Infants: Results from the French Prospective National EPIPAGE 2 Cohort. J		
	<ul> <li>Pediatr. 2021 May; 232:38-47.</li> <li>17. Van Alfen-van der Velden AA, Hopman JC, Klaessens JH, Feuth T, Sengers RC, Liem KD. Effects of midazolam and morphine on cerebral oxygenation and hemodynamics in ventilated premature infante. Biology of the Neonete 2006;00(2):107–202.</li> </ul>		
	<ul> <li>infants. Biology of the Neonate. 2006;90(3):197–202.</li> <li>18. Burtin P, Daoud P, Jacqz-Aigrain E, Mussat P, Moriette G. Hypotension with midazolam and fentanyl in the newborn. Lancet. Jun 22, 1991;337(8756):1545–1546</li> </ul>		
	<ol> <li>Bernet V, Latal B, Natalucci G, Doell C, Ziegler A, Wohlrab G. Effect of sedation and analgesia on postoperative amplitude-integrated EEG in newborn cardiac patients. Pediatr Res. Jun 2010;67(6):650–655.</li> </ol>		

20.	De Wildt SN, Kearns GL, Hop WC, Murry DJ, Abdel-Rahman SM, van den Anker JN. Pharmacokinetics
	and metabolism of intravenous midazolam in preterm infants. Clin Pharmacol Ther. 2001
	Dec;70(6):525–31.
21.	Taketomo CK, Hodding JH, Kraus DM, American Pharmacists Association. Pediatric and neonatal
	dosage handbook. Hudson, Ohio: Lexi-Comp: American Pharmacists Association; 2015.
22.	MerativeTM Micromedex <sup>®</sup> Complete IV Compatibility (electronic version). Merative, Ann Arbor,
	Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: Aug/15/2024).
23.	Senarathna SMDKG, Strunk T, Petrovski M, Woodland S, Martinez J, Chuang VTG, Batty KT. Physical
	compatibility of lipid emulsions and intravenous medications used in neonatal intensive care
	settings. Eur J Hosp Pharm 2023; In press; doi:10.1136/ejhpharm-2023-003870.
24.	Pansini V, Curatola A, Gatto A, Lazzareschi I, Ruggiero A, Chiaretti A. Intranasal drugs for analgesia
	and sedation in children admitted to pediatric emergency department: a narrative review. Annals of
	translational medicine. 2021 Jan;9(2).

VERSION/NUMBER	DATE
Original 1.2	23/03/2016
Version 2.0	26/04/2021
Version 3.0	16/09/2021
Current 4.0	16/09/2024
REVIEW	16/09/2029

## Authors Contribution of the current version

Nilkant Phad, Srinivas Bolisetty		
David Osborn, Nilkant Phad		
Benjamin Emerson-Parker		
Thao Tran, Michelle Jenkins, Rebecca O'Grady		
Bhavesh Mehta, Rebecca Barzegar, Kerryn Houghton, Martin Kluckow, Mohammad		
Irfan Azeem, Susanah Brew, Thao Tran, Michelle Jenkins, Stephanie Halena, Natalia		
Srnic, Renae Gengaroli, Bryony Malloy, Samantha Hassall		
Nilkant Phad, Thao Tran, Benjamin Emerson-Parker		
Thao Tran, Natalia Srnic, Cindy Chen, Ian Callander		
Srinivas Bolisetty		

## Citation for the current version

Phad N, Bolisetty S, Osborn D, Emerson-Parker B, Tran T, Jenkins M, O'Grady R, Mehta B, Barzegar R, Houghton K, Kluckow M, Azeem MI, Brew S, Halena S, Srnic N, Gengaroli R, Malloy B, Hassall S, Callander I. Midazolam. Consensus formulary by the Australasian Neonatal Medicines Formulary group. Version 4 dated 16 September 2024. www.anmfonline.org